Why the study?
What is the risk of first-dose hypotension when initiating ACE inhibitors, and how should it be managed?
What is the risk of first-dose hypotension when initiating ACE inhibitors, and how should it be managed?
ACE inhibitors can cause severe first-dose hypotension in about 10% of high-risk patients, necessitating initiation at the minimum effective dose and close observation for at least 6 hours.
Answers are grounded in this paper and cite their sources.
Supports cautious low-dose ACE inhibitor initiation with monitoring in high-risk patients; leaves open optimal risk-stratification strategies.
A fall in blood pressure occurs, in most patients, within a few hours of a single dose of an angiotensin converting enzyme (ACE) inhibitor. While a serious fall in pressure is unusual in previously untreated essential hypertension, some patients are at risk of severe first-dose hypotension. These include those with treated heart failure, severe hypertension on polypharmacy, 'renin-dependent' renovascular hypertension and the occasional elderly patient. In such groups of patients the incidence of severe, symptomatic first-dose hypotension approaches 10%. This effect is not specific for ACE inhibitor therapy and may well occur as frequently with other drugs in such patients. First-dose hypotension may not be accompanied by tachycardia, possibly as a result of a parasympathomimetic action that may contribute to the first-dose effect. It is generally not possible to predict patients at risk, although plasma renin and angiotensin II concentrations show a modest positive correlation with the initial fall in blood pressure. The maximum initial hypotensive effect of ACE inhibitors is not clearly dose related but the duration of effect may be. Therefore such drugs should be started at minimum effective dosage. High-risk patients should be observed closely for at least 6 h. Symptomatic hypotension usually responds to supine rest although infusion of angiotensin II, atropine and occasionally saline may be required.
No takes yet. Share an insight, caveat, or question.
John Webster (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: